NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Nasus Pharma Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026
$3.21+0.02 (+0.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Nasus Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Market Cap | $28.89M | $166.30M |
| Enterprise Value | $21.08M | $88.19M |
| PS Ratio | 0.02 | 3.65 |
| PB Ratio | 2.63 | 2.03 |
| P/TBV Ratio | 2.63 | 2.29 |
Enterprise value
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| EV / Sales | 0.02 | 2.51 |
Income (trailing twelve months)
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Revenue | $1.24B | $58.34M |
| Operating Income | -$4.90M | -$21.40M |
| Net Income | -$5.86M | -$22.46M |
| EBITDA | -$4.90M | -$16.91M |
| EPS (Diluted) | -$0.72 | -$0.83 |
Margins
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Operating Margin | -0.40% | -44.0% |
| Profit Margin | -0.47% | -40.2% |
| EBITDA Margin | -0.40% | -30.2% |
| FCF Margin | -0.40% | -9.27% |
Returns
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -175.3% | -53.2% |
| Return on Assets (ROA) | -89.5% | -40.9% |
| Return on Capital Employed (ROCE) | -44.4% | -38.1% |
Balance sheet
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.82M | $61.43M |
| Net Cash (Debt) | $7.82M | $15.35M |
| Net Cash Per Share | $0.87 | $0.66 |
| Equity (Book Value) | $11.00M | $49.09M |
| Book Value Per Share | $1.22 | $1.37 |
| Tangible Book Value | $11.00M | $23.52M |
| Working Capital | $10.91M | $76.81M |
Financial position
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Current Ratio | 8.77 | 3.34 |
| Quick Ratio | 5.57 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$4.92M | -$12.35M |
| Capital Expenditures | -$14.00K | -$1.08M |
| Free Cash Flow | -$4.93M | -$20.22M |
| FCF Per Share | -$0.55 | -$0.42 |
Efficiency
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Asset Turnover | 188.72 | 0.39 |
Dividends and yields
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Earnings Yield | -20.3% | -23.3% |
| FCF Yield | -17.1% | -8.72% |
| Buyback Yield | -29.4% | -0.59% |
| Shareholder Yield | -29.4% | 0.00% |
Shares
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 9,015,380 | 58,127,000 |
| Shares Change (YoY) | 14.0% | 10.9% |
| Float | 3,672,950 | 49,136,700 |
| Shares Held by Insiders | 59.3% | 11.6% |
Scores
| Measure | Nasus Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 108.14 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Nasus Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.